Manufacturer restricts use of diabetes drug Avandia
Last Updated: Wednesday, November 7, 2007 | 4:37 PM ET
The Canadian Press
The manufacturer of a drug for treating Type 2 diabetes has placed new restrictions on use of the medication based on a Health Canada review of clinical data pointing to an increased risk of heart-related problems in some patients.
GlaxoSmithKline Inc., in consultation with Health Canada, is updating prescribing information on products made from or containing the drug rosiglitazone: Avandia, Avandamet and AvandarylTM.
Once touted as the gold standard for preventing Type 2 diabetes in high-risk patients, rosiglitazone lost its glitter after a study published in the New England Journal of Medicine in May showed Avandia significantly raised the risk of heart attack and possible death.
The NEJM analysis of 42 studies revealed a 43 per cent higher risk of heart attack for those taking rosiglitazone compared to people taking other diabetes drugs or no diabetes medication at all.
In new prescribing information, GlaxoSmithKline said patients may take Avandia in combination with metformin when good blood-sugar control does not result with metformin alone. Metformin is an anti-diabetic drug sold under the brand names Glucophage, Glumetza or in generic forms with "metformin" as part of the name.
As well, "Avandia may be used alone or with a sulfonylurea drug [such as glyburide], only if metformin use is contraindicated or cannot be tolerated," the company said in a release.
"The new labelling also emphasizes that Avandia should not be used in patients with any stage of heart failure."
Glaxo said patients taking rosiglitazone and especially those with underlying heart disease or with a high risk of heart attack or heart failure should talk to their doctor about the benefits and risks of continuing the drug.
Other important restrictions for patients:
- Rosiglitazone should not be taken if insulin is also being used.
- Rosiglitazone should not be used as part of a "triple therapy" in combination with metformin and a sulfonylurea drug.
Rosiglitazone can cause the body to retain fluid, which can worsen some heart problems and lead to heart failure, swelling and weight gain.
Several lawsuits have been launched in Canada and the United States over the medication's adverse effects, and drug safety regulators in both countries have been investigating its safety.
Share Tools
Top News Headlines
- Teen struck by lightning in Ottawa dies
- The victim of a Friday lightning strike during a storm in east Ottawa has died, CBC News has learned. more »
- Montreal protesters march in peaceful defiance
- The clanging of pots and pans sounded throughout Montreal's downtown core Saturday night and into early Sunday morning, as thousands of protesters marched on in peaceful — but loud — defiance of Bill 78. more »
- Syrian children massacred by the dozens, UN says
- More than 90 people have been killed by regime forces in a district of central Syria, with the head of the UN team in the country confirming at least 32 children and 60 adults were killed in an artillery attack. more »
- Missing Winnipeg children found in Mexico
- Two Winnipeg children reported missing and possibly in Mexico have been found alive, according to unofficial reports from an agency that works to find missing people. more »
- Teen struck by lightning in Ottawa dies
- Missing Winnipeg children found in Mexico
- Quebec tornadoes cause millions in damage
- Everest team unable to bring down Toronto woman's body
- Pope's butler arrested in Vatican leaks scandal
- Woman's remains found in hockey bag on Cape Breton river
- WWE apologizes to Brazil over Canadian's flag stomp
- Syrian children massacred by the dozens, UN says
- N.L. premier 'at odds' with Peter MacKay
